Interpretation of ASTCT Consensus Responses by Chimeric Antigen Receptor T Cell Therapy CRS/ICANS--Review.
10.19746/j.cnki.issn.1009-2137.2021.06.051
- Author:
Cheng-Cheng FU
1
;
Ru-Ju WANG
1
;
De-Pei WU
2
Author Information
1. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematology, Suzhou 215006, Jiangsu Province, China.
2. The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, National Clinical Research Center for Hematology, Suzhou 215006, Jiangsu Province, China .E-mail: wudepei@suda.edu.cn.
- Publication Type:Multicenter Study
- MeSH:
Cell- and Tissue-Based Therapy;
Consensus;
Cytokine Release Syndrome;
Humans;
Receptors, Antigen, T-Cell;
Receptors, Chimeric Antigen
- From:
Journal of Experimental Hematology
2021;29(6):1982-1986
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell (CAR-T) therapy was awarded as the largest research breakthrough in 2017 by the American Society of Clinical Oncology, at present, it is rapidly becoming the most promising new treatment for hematological malignancies. However, this therapy also produces a new challenge: toxic adverse events such as cytokine release syndrome (CRS) and neurotoxicity, partial of them can bring death to the patients. The incidence and severity of the above toxic events in different multi-center trial reports are also different, which may be attributed to the different in the considerably variable assessment and grading of toxicities between clinical trials and across institutions. The ASTCT published at 2018 advanced the consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells, it was focusing on CRS and neurotoxicity associated with immune effector cells. In order to provide reference for the development of relevant work in this field and the formulation of security strategies in our country, the main content of the consensus was summarized briefly.
